139 related articles for article (PubMed ID: 31169796)
21. Congestive heart failure: what should be the initial therapy and why?
Chatterjee K
Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults.
Aronow WS
Heart Fail Clin; 2017 Jul; 13(3):467-483. PubMed ID: 28602366
[TBL] [Abstract][Full Text] [Related]
23. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
[TBL] [Abstract][Full Text] [Related]
24. Drug therapy for congestive heart failure. Appropriate choices can prolong life.
Sorrentino MJ
Postgrad Med; 1997 Jan; 101(1):83-6, 89-90, 93-4. PubMed ID: 9008690
[TBL] [Abstract][Full Text] [Related]
25. 2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines.
Hitzeroth J; Mpe M; Klug E; Ranjith N; Sliwa K; Steingo L; Lachman L; Tsabedze N; Ntusi NAB; Society Of South Africa HF
S Afr Med J; 2020 Aug; 110(8b):13057. PubMed ID: 32880257
[TBL] [Abstract][Full Text] [Related]
26. New Management Strategies in Heart Failure.
Owens AT; Brozena SC; Jessup M
Circ Res; 2016 Feb; 118(3):480-95. PubMed ID: 26846642
[TBL] [Abstract][Full Text] [Related]
27. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
Saito M; Nakayama D; Takada M; Hirooka K; Yasumura Y
J Clin Pharm Ther; 2006 Dec; 31(6):535-40. PubMed ID: 17176359
[TBL] [Abstract][Full Text] [Related]
28. Drug-patient interactions and their relevance in the treatment of heart failure.
Johnston D; Duffin D
Am J Cardiol; 1992 Oct; 70(10):109C-112C. PubMed ID: 1329465
[TBL] [Abstract][Full Text] [Related]
29. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
Aronow WS
J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).
Ogawa R; Stachnik JM; Echizen H
Clin Pharmacokinet; 2014 Dec; 53(12):1083-114. PubMed ID: 25248847
[TBL] [Abstract][Full Text] [Related]
32. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
33. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
[TBL] [Abstract][Full Text] [Related]
34. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
35. Challenging the dogma of high target doses in the treatment of heart failure: is more always better?
Follath F
Arch Cardiovasc Dis; 2009 Nov; 102(11):785-9. PubMed ID: 19944395
[TBL] [Abstract][Full Text] [Related]
36. Eplerenone in the treatment of chronic heart failure.
Krum H; Liew D
Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
[TBL] [Abstract][Full Text] [Related]
37. [Heart failure and treatment of ventricular arrhythmias].
Junga G; Duru F; Candinas R
Praxis (Bern 1994); 1999 Feb; 88(6):215-22. PubMed ID: 10081339
[TBL] [Abstract][Full Text] [Related]
38. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
39. The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects.
Knauf H; Bailey MA; Hasenfuss G; Mutschler E
Eur J Clin Pharmacol; 2006 Nov; 62(11):885-92. PubMed ID: 16964522
[TBL] [Abstract][Full Text] [Related]
40. [Contemporary approaches to diagnosis and management of chronic heart failure (summary of the American College of Cardiology/American Heart Association Guidelines)].
Sidorenko BA; Preobrazhensky DV; Batyraliev TA; Marenitch AV; Romanova NE
Kardiologiia; 2002; 42(6):65-78. PubMed ID: 12494135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
